Source Post
Nothing can save your hairline #hairloss #investing #stocks #minoxidil #balding
Dec 8, 2025
The creator discusses Cosmo Pharmaceuticals NV (COPN) and its new hair loss drug, highlighting its impressive Phase III trial results and significant stock price increase. Despite the promising data and market potential, the creator expresses skepticism about the drug being a permanent solution and states they are not buying the stock.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.